Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients

The efficacy of combined treatment in active acromegaly with both long-acting somatostatin analogs (SRIF) and pegvisomant (PEG-V) has been well established. The aim was to describe the PEG-V dose reductions after the conversion from daily PEG-V to combination treatment. To clarify the individual ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Neggers, Sebastian J. C. M. M., de Herder, Wouter W., Feelders, Richard A., van der Lely, A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146981/
https://www.ncbi.nlm.nih.gov/pubmed/21221818
http://dx.doi.org/10.1007/s11102-010-0289-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146981/
https://www.ncbi.nlm.nih.gov/pubmed/21221818
http://dx.doi.org/10.1007/s11102-010-0289-5

Ejemplares similares